این سایت در حال حاضر پشتیبانی نمی شود و امکان دارد داده های نشریات بروز نباشند
Iranian Journal of Nuclear Medicine، جلد ۲۱، شماره ۱، صفحات ۲۶-۳۲
عنوان فارسی
چکیده فارسی مقاله
کلیدواژه‌های فارسی مقاله
عنوان انگلیسی Effectiveness and complications of 153Sm-EDTMP in palliative treatment of diffuse skeletal metastases
چکیده انگلیسی مقاله Introduction: The aim of the present study was to evaluate the efficacy and safety profile of bone palliative therapy following administration of 153Sm-EDTMP in patients with intractable metastatic bone pain. Methods: Sixteen patients (9 male, 7 female) aged 29-80 years (57.3±16.7 years) with severe metastasis-related bone pain resistant to analgesic medications were enrolled in the study. All patients having multiple bone metastases, positive bone scans, and estimated life expectancy of more than 2-3 months were entered the study. All patients received intravenous injection of 1.5 mCi (56 MBq)/kg of 153Sm-EDTMP. Four subscales for the intensity of pain were recorded: one as the present pain score (PPS) and the other three as maximum pain score (Max PS), minimum pain score (Min PS) and average pain score (APS) over the last 24 hours. Also the mean value of these 4 subscales was calculated as the mean total pain score (MTPS). The pain mental interference (PMI) was also assessed in 9 separate. Results: Seven patients with breast cancer (43.75%), seven with prostate cancer (43.75%), one with papillary thyroid carcinoma (6.25%) and one with malignant paraganglioma (6.25%) were included in the study. A significant response to therapy, i.e. 2-point reduction in pain score and/or remarkable reduction (³25%) in the equivalent narcotic dose, was observed in 11 out of 16 patients (68.7%) by the 2nd week and in 12 patients (75%) by the 8th week. Regarding the palliative response to treatment and equivalent narcotic dose reduction, no significant difference between two major types of underlying malignancies (breast and prostate cancer) was found. There was no significant difference regarding response to therapy between two genders and among different age groups. The severity of bone marrow suppression was graded ≤2 in all patients. Conclusion: Response to palliative treatment with 153Sm-EDTMP in prostate and breast cancers is the same at the rate of 75% at the end of 8th week post-infusion. Hematologic toxicity is mild to moderate and no life-threatening side effect is observed.
کلیدواژه‌های انگلیسی مقاله 153Sm-EDTMP,Palliative therapy,Pain,Bone metastasis
نویسندگان مقاله داود بیکی |
research center for nuclear medicine, tehran university of medical sciences, tehran, iran
سازمان اصلی تایید شده: دانشگاه علوم پزشکی تهران (Tehran university of medical sciences)

پیمان حداد |
department of radiation oncology, cancer research center, cancer institute, tehran university of medical sciences, iran
سازمان اصلی تایید شده: دانشگاه علوم پزشکی تهران (Tehran university of medical sciences)

بابک فلاحی |
research center for nuclear medicine, tehran university of medical sciences, tehran, iran
سازمان اصلی تایید شده: دانشگاه علوم پزشکی تهران (Tehran university of medical sciences)

آرش کیوان |
research center for nuclear medicine, tehran university of medical sciences, tehran, iran
سازمان اصلی تایید شده: دانشگاه علوم پزشکی تهران (Tehran university of medical sciences)

علی gholamrezanezhad |
research center for nuclear medicine, tehran university of medical sciences, tehran, iran
سازمان اصلی تایید شده: دانشگاه علوم پزشکی تهران (Tehran university of medical sciences)

حمیدرضا میرزایی |
radiation oncology department, cancer research center, shohada-e-tajrish hospital, shaheed beheshti university of medical sciences, tehran, iran
سازمان اصلی تایید شده: دانشگاه علوم پزشکی شهید بهشتی (Shahid beheshti university of medical sciences)

محسن ساغری |
research center for nuclear medicine, tehran university of medical sciences, tehran, iran
سازمان اصلی تایید شده: دانشگاه علوم پزشکی تهران (Tehran university of medical sciences)

فرناز فرناز | amouzegar hashemi
department of radiation oncology, cancer research center, cancer institute, tehran university of medical sciences, iran
سازمان اصلی تایید شده: دانشگاه علوم پزشکی تهران (Tehran university of medical sciences)

علی کاظمیان |
department of radiation oncology, cancer research center, cancer institute, tehran university of medical sciences, iran
سازمان اصلی تایید شده: دانشگاه علوم پزشکی تهران (Tehran university of medical sciences)

ارمغان فرد اصفهانی | fard esfahani
research center for nuclear medicine, tehran university of medical sciences, tehran, iran
سازمان اصلی تایید شده: دانشگاه علوم پزشکی تهران (Tehran university of medical sciences)

محمد افتخاری |
research center for nuclear medicine, tehran university of medical sciences, tehran, iran
سازمان اصلی تایید شده: دانشگاه علوم پزشکی تهران (Tehran university of medical sciences)

نشانی اینترنتی http://irjnm.tums.ac.ir/article_2563_3220098ef0d4a7d038d11460fa3632dc.pdf
فایل مقاله فایلی برای مقاله ذخیره نشده است
کد مقاله (doi)
زبان مقاله منتشر شده en
موضوعات مقاله منتشر شده
نوع مقاله منتشر شده
برگشت به: صفحه اول پایگاه   |   نسخه مرتبط   |   نشریه مرتبط   |   فهرست نشریات